Processing

Please wait...

Settings

Settings

Goto Application

1. WO2023009770 - METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY

Publication Number WO/2023/009770
Publication Date 02.02.2023
International Application No. PCT/US2022/038749
International Filing Date 29.07.2022
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • TEVOGEN BIO, INC. [US]/[US]
Inventors
  • SAADI, Ryan
Agents
  • CONNARN, Kristin, A.
Priority Data
63/227,69030.07.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY
(FR) PROCÉDÉS DE DÉVELOPPEMENT DE CELLULES CD3+ CD8+ CONTRE DE MULTIPLES ÉPITOPES VIRAUX POUR LE TRAITEMENT D'INFECTIONS VIRALES NOTAMMENT DE VARIANTS ÉVOLUANT POUR ÉCHAPPER À L'IMMUNITÉ PRÉCÉDENTE
Abstract
(EN) Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide- diluted peptide composition; and sensitizing mononuclear cells with an immunodominant- peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.
(FR) L'invention concerne des procédés de préparation de lymphocytes T cytotoxiques (CTL) spécifiques à un peptide contre une souche d'un virus ayant émergé. Les procédés consistent à utiliser une composition peptidique initiale spécifique à une souche précédente d'un virus, contre laquelle les CTL antérieurs ont été sensibilisés, les CTL antérieurs ayant une efficacité réduite contre une souche d'un virus ayant émergé par rapport à leur efficacité contre la souche précédente du virus ; à identifier un peptide immunodominant contre une souche précédente d'un virus dans une composition peptidique initiale ; à réduire la proportion d'un peptide immunodominant dans une composition peptidique initiale en vue de produire une composition peptidique diluée en peptide immunodominant ; et à sensibiliser des cellules mononucléaires avec une composition peptidique diluée en peptide immunodominant, ce qui permet de produire une expansion des CTL spécifiques à un peptide contre une souche d'un virus ayant émergé. Le virus peut être le SARS-COV2 (COVID-19) et la souche ayant émergé peut être Delta ou Omicron BA.2.75.
Latest bibliographic data on file with the International Bureau